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doi:10.1016/j.asjsur.2012.04.010Summary Background: Obesity and type II diabetes mellitus (T2DM) are closely related and
difficult to control by current medical treatment. Bariatric surgery has been proposed for inad-
equately controlled T2DM in association with obesity. However, prediction of successful T2DM
remission after surgery has not been clearly studied in Asian patients. This information might
be helpful for applying gastrointestinal surgery as metabolic surgery for T2DM.
Methods: This was a retrospective clinical study. From January 2002 to December 2008, 88
consecutive patients with morbid obesity, who were enrolled into a surgically supervised
weight loss program, and who had T2DM before surgery with at least 1 year complete
follow-up data were included. Sixty-eight (77.2%) patients received gastric bypass procedures,
and the remaining 20 (22.8%) received restrictive procedures. We analyzed the available infor-
mation during the initial evaluation of patients who were referred for bariatric surgery, by
logistic regression analysis and data mining methods for predictors of successful diabetes
remission after surgery.
Results: Overall, 68 (77.2%) of the 88 patients had remission of their T2DM 1 year after
surgery. Patients in the bypass group had a higher remission rate than those in the restrictive
group [59/68 (86.7%) vs. 9/20 (45.0%), pZ 0.000]. In univariate analysis, patients who had
T2DM remission after surgery were younger, heavier, had a wider waist, less severe disease,
shorter duration, and higher C-peptide levels than those without remission. Type of opera-
tion and T2DM duration remained independent predictors of success after multivariate logis-
tical regression analysis (p< 0.000). Data mining analysis confirmed that T2DM duration was
the most important predictor.of Surgery, Min-Sheng General Hospital, No. 168, Chin Kuo Road, Tauoyan, Taiwan, ROC.
@yahoo.com.tw (W.-J. Lee).
n Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
68 W.-J. Lee et al.Conclusions: Bariatric surgery is a treatment option for T2DM. Duration of diabetes is the
most predictor of success after surgery.
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reserved.1. Introduction
Obesity and its associated type 2 diabetes mellitus (T2DM)
are an ongoing health-care problem worldwide.1,2 Both
diseases are closely related anddifficult to control by current
medical treatment, including diet, drug therapy and behav-
ioralmodification.3e5 Gastrointestinal surgery, performed as
bariatric surgery, has been the most powerful ammunition
for obesity treatment. There is strong evidence that bariatric
surgery can curemost of the associatedT2DM inpatientswith
morbid obesity.6e11 Remission of diabetes has been found to
be associated with a range of excess weight loss after
surgery.8,9 Current consensus for bariatric surgery is set at
body mass index (BMI) > 35 kg/m2 with comorbidity but
gastrointestinal metabolic surgery recently has been
proposed as a new treatment modality for obesity-related
T2DM for patients with BMI < 35 kg/m2.12e15 However,
optimal outcomes for diabetes remission after bariatric
surgery will occur if patients who are best suited to the
surgery are selected and those who will predictably have
a poor result are excluded.16 Furthermore, it could be that
certain categories of patients are better suited to one type of
bariatric procedure. To be able to make such decisions, we
need preoperative information on the association between
possible predictors and outcome.
The aim of this study was to examine the efficacy of
surgically induced weight loss on diabetes remission.
Furthermore, we looked for the preoperative predictors of
diabetes remission after bariatric surgery.
2. Patients and methods
2.1. Patients
From January 2002 to December 2008, 88 (10.8 %) out of
811 patients who were enrolled in a surgically supervised
program for weight reduction, and who had T2DM before
surgery with at least 1 year follow-up, were retrospectively
identified and included. There were 53 female and 35 male
patients with a mean age of 35.7 years (range: 18e64 years)
and a mean BMI of 39.5 kg/m2 (range: 30.0e61.7 kg/m2).
Diagnosis and classification of T2DM was based on fasting
plasma glucose concentrations S 126 mg/dL or those with
positive history and under antidiabetic medications.17
Remission of diabetes was defined in this study as a fast-
ing plasma glucose level < 110 mg/dL or hemoglobin (Hb)
A1C level < 6.4% without hypoglycemic medication at 1
year after surgery. The institutional review board approved
this study.
Blood was drawn for laboratory examination from an
antecubital vein following an overnight fast. The test was
measured on the Hitachi 7170 and with the J&Jnepholometer assay (Dade Behring, USA). C-peptide levels
were measured with DPC Immulite analyzer. All specimens
were processed within 24 hours of collection and then
stored at e30C until assay. Insulin resistance (IR) was
measured by homeostatic model assessmenteinsulin resis-
tance (HOMA-IR) index, which can be calculated as plasma
glucose (mmol/L) insulin (IU/mL)/22.5.18
2.2. Interventions
Among the 88 patients in the study group, the surgical
procedures performed included restrictive type in 20
(22.8%) patients and gastric bypass procedures in 68 (77.2%)
patients. The restrictive procedures included laparoscopic
adjustable gastric banding (LAGB, using Lap Ban from
Bioenterics Corp., Carpinteria, CA, USA) in seven patients,
and laparoscopic sleeve gastrectomy (LSG) in 13 patients.
The gastric bypass included laparoscopic mini-gastric
bypass (LMGBP) in 68 patients. The techniques of LAGB
and LMGBP are described in detail elsewhere.19e21 All
procedures were performed by laparoscopic surgery. No
drain was left. All the trocar wounds were closed by the
mesh plug technique using bioabsorbable hemostatic gauze
(Cellulostat, Horng Tzer Medical Instruments, Kaohsiung,
Taiwan).22 The patients chose either procedure after
discussion with a surgeon on an individual basis. There was
no operative mortality in this series. One patient (1.1%)
developed a major complication of leakage and five (5.6%)
had minor complications.
2.3. Statistical analyses
All statistical analyses were performed using SPSS version
12.01 (SPSS Inc., Chicago, IL, USA), with baseline compar-
ison made using c2 tests and two-sample t tests. Continuous
variables were expressed as mean standard deviation
(SD), with differences expressed as mean SD. A two-sided
p value < 0.05 was considered statistically significant.
We performed a predictor of diabetes resolution analysis
using binary logistic regression, and adatamining technology
of artificial neural networks (ANNs) was used to examine the
associates of diabetes remission. Neural networks mimic
human neurobiological information-processing activities.
Analyses applied in this study were Back Propagation Neural
networks (BPNs) conformed to a three-layered perception
architecture. All preoperative factors were set as the input
nodes in the input layer with only one dependent factor
(successful diabetes remission) as the output node in the
output layer. Details of this analysis have been described
previously.23,24 We further compared the performance of
ANNs and the logistic regression model by using the cross-
validation method. ANNs were constructed using Qnet97
(Vesta Services Inc., 1998).
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3.1. Patient characteristics and weight loss after
surgery
The preoperative clinical characteristics of all patients are
shown in Table 1. Among the clinical characteristics of the
study patients receiving different surgical procedures,
patients with older age, lesser degrees of obesity, and
longer duration of diabetes preferred the restrictive mode
of surgery at baseline (Table 1). The accompanying meta-
bolic parameters were comparable for blood pressure,
fasting plasma glucose, and plasma lipid levels between
both groups.
At 1 year after surgery, with a greater body weight loss
in the gastric bypass group than in the restrictive group
(35.0 16.1 vs. 18.7 11.2 kg, p< 0.0001), individuals who
underwent gastric bypass experienced a higher rate of
excess weight loss (69.4 19.3% vs. 52.0 30.3%,
pZ 0.021) and achieved a similar BMI (28.3 5.0 vs.
29.5 7.1 kg/m2, pZ 0.854) compared to individuals who
underwent restrictive type surgery.
3.2. Diabetes remission and other health outcomes
Remission of T2DM was achieved in a total of 68 (77.2%)
patients at 1 year after bariatric surgery. Patients in the
bypass group had a higher diabetes remission rate than
those in the restrictive group [59/68 (86.7%) vs. 9/20
(45.0%), pZ 0.000]. The accompanying metabolic param-
eters, that is, fasting plasma glucose, blood lipid levels andTable 1 Clinical and metabolic features in the gastric






Age (yr) 34.4 10.7 40.4 11.2 0.024*
Sex, M/F 28/40 7/13 0.620
BMI (kg/m2) 40.5 8.0 36.2 5.6 0.034*
Waist (cm) 120.0 15.9 113.6 16.3 0.073
SBP (mmHg) 136.0 15.1 130.7 11.9 0.262
DBP (mmHg) 81.1 9.9 81.4 7.8 0.984
FPG (mg/dL) 207.7 87.1 230.1 92.9 0.458
Total
cholesterol (mg/dL)
206.4 49.0 214.6 52.9 0.690
Triglyceride (mg/dL) 280.9 287.4 273.3 151.4 0.165
HDL-C (mg/dL) 44.4 21.1 40.2 7.7 0.494
HbA1C (%) 8.4 2.2 8.9 2.5 0.433
C-peptide (ng/mL) 5.3 3.4 5.2 4.3 0.552
HOMA-IR 17.9 23.3 16.4 19.2 0.986
Metabolic syndrome 53 (77.9%) 17 (85%) 0.355
Duration of DM (yr) 1.6 3.7 3.8 4.0 0.002*
Insulin case (no.) 2 (2.9%) 2 (10%) 0.183
*p< 0.05. BMIZ body mass index; DBPZ diastolic blood pres-
sure; DMZ diabetes mellitus; FZ female; FPGZ fasting
plasma glucose; HbA1cZ hemoglobin A1c; HDL-CZ high-
density lipoprotein cholesterol; HOMA-IRZ Homeostasis model
assessmenteinsulin resistance17; MZmale; SBPZ systolic
blood pressure.HbA1c significantly improved in the individuals who
underwent gastric bypass surgery (Table 2). The degree of
IR was also much better in the individuals who underwent
gastric bypass surgery, with a lower level of fasting insulin/
C-peptide and HOMA-IR index. The patients who underwent
gastric bypass surgery manifested a lower frequency of
metabolic syndrome (10.2% vs. 50%, p< 0.001) and reached
a higher rate of diabetes remission (86.7% vs. 45%;
p< 0.001), as shown in Table 2.
3.3. Predictor analyses for diabetes remission
We used two methods to identify preoperative factors that
were likely to predict diabetes remission after surgical
treatment. Logistic regression analysis between those with
and without T2DM remission disclosed 12 positive preop-
erative clinical predictors of remission (Table 3). In the
more obese patients who had a higher BMI, weight had
better remission 1 year after surgery. Patients with more
severe status in insulin and C-peptide and shorter T2DM
history had a better remission rate. Multivariate analysis
confirmed that the mode of operation and duration of T2DM
history had significant effects on remission (p< 0.0001).
The average correct classification rate of logistic regression
was 85.9% (Table 4).
Consistent with the logistic regression model, ANNs also
confirmed that duration of T2DM history was the most
important predictor of diabetes remission after surgery.
Age was another independent predictor but not type of
surgery. Fig. 1 shows the relative importance of preopera-
tive predictor variables. The average correct classification
rate of the BPN model was 90.4%.Table 2 Clinical and metabolic features in the gastric







BMI (kg/m2) 28.3 5.0 29.5 7.1 0.854
% of BMI loss 30.1% 18.5% 0.001*
Waist (cm) 92.4 13.5 93.8 16.5 0.815
SBP (mmHg) 124.1 16.2 128.8 15.3 0.290
DBP (mmHg) 74.5 11.2 77.1 11.0 0.561
FPG (mg/dL) 90.0 19.1 121.1 44.8 0.000*
Total
cholesterol (mg/dL)
159.1 29.5 194.3 25.5 0.000*
Triglyceride (mg/dL) 88.6 41.6 145.0 66.1 0.000*
HDL-C (mg/dL) 47.8 12.7 44.8 7.3 0.473
HbA1C (%) 5.3 0.5 6.5 1.2 0.000*
C-peptide (ng/mL) 1.7 0.9 2.3 1.3 0.014*
HOMA-IR 1.1 1.0 2.6 2.2 0.002*
Metabolic syndrome 7 (10.2%) 10 (50%) 0.000*
DM remission 59 (86.7%) 9 (45%) 0.000*
*p< 0.05. BMIZ body mass index; DBPZ diastolic blood pres-
sure; DMZ diabetes mellitus; FPGZ fasting plasma glucose;
HbA1cZ hemoglobin A1c; HDL-CZ high-density lipoprotein
cholesterol; HOMA-IRZ homeostasis model assessmenteinsulin
resistance17; SBPZ systolic blood pressure.
Table 3 Univariate analysis of preoperative factors in






Age, yr 44.4 9.7 33.2 10.2 0.000*
Weight (kg) 92.3 19.5 115.0 25.9 0.000*
BMI (kg/m2) 34.3 4.3 41.1 7.8 0.000*
Waist (cm) 111.5 12.1 120.7 16.6 0.010*
FPG (mg/dL) 247.6 84.9 202.6 87.4 0.038*
AST (IU/L) 28.1 15.8 44.5 27.5 0.013*
ALT (IU/L) 37.9 24.8 69.6 50.2 0.004*
Insulin (IU/L) 17.6 15.6 47.2 70.4 0.020*
HbA1C (%) 9.8 2.3 8.2 2.1 0.006*
C-peptide (ng/mL) 3.4 1.6 5.9 3.9 0.004*
Duration of DM (yr) 6.1 5.2 0.9 2.3 0.000*
Insulin case (no.) 4 (20%) 0 (0%) 0.000*
*p< 0.05. ALTZ alanine aminotransferase; ALTZ aspartate
aminotransferase; BMIZ body mass index; DMZ diabetes mel-
litus; FPGZ fasting plasma glucose; HbA1cZ hemoglobin A1c.
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The T2DM remission rates for those with disease duration< 2
years, 2e5 years and > 5 years were 57/59 (98.5%), 7/17
(39.3%) and 4/12 (37.3%), respectively (p< 0.001) (Table 5).
For the restrictive group, the remission rate was 100% in
patients with duration of T2DM < 2 years. The T2DM remis-
sion rates for those with preoperative C-peptide < 3 ng/mL,
3e6 ng/mL and> 6 ng/mL were 9/18 (60.0%), 25/33 (75.7%)
and 19/21 (90.1%), respectively (pZ 0.001) (Table 6). The
T2DM remission rate dropped dramatically in the restrictive
group for patients with C-peptide < 6 ng/mL. Both duration
of T2DM and C-peptide level had a significant predictive
power for diabetes remission in the restrictive group
compared with the bypass group.
4. Discussion
In this report, we show that bariatric surgery is a promising
treatment for obese Asian patients with inadequately
controlled T2DM. The overall 1-year remission rate was
77.9% for a group of T2DM patients with mean HbA1c of
8.6%. In previous studies by Pories et al and Shauer et al,
the resolution rate of T2DM in Caucasian patients with
morbid obesity after gastric bypass was 88%, which agrees
with our study.6,25 Successful remission of T2DM in this
group of patients can be translated to a decrease in
diabetes-related mortality. Recent studies have disclosed
that bariatric surgery can reduce mortality by up to
30e40%, and more important is that the reduction ofTable 4 Multivariate analysis of preoperative predictors
of remission.
Factor 95% CI p value
Operative methods 0.000e0.212 0.000*
Diabetes duration 0.020e2.126 0.000*
*p< 0.05.mortality by bariatric surgery is mostly attributed to the
reduction in diabetes-related death.10,11 These data
constitute a good argument for proposing metabolic surgery
in inadequately controlled obesity-related T2DM patients as
soon as possible.
The most important finding of the present study was that
duration of T2DM was the most important predictor of
diabetes remission after surgery. Old age, longer T2DM
history and use of insulin have been found to be negative
predictors of T2DM remission in previous studies of bariatric
surgery in patients with morbid obesity.6,26 However, no
data were available for Asian patients. The duration of
T2DM turned out to be the most important predictor for
Asian patients in our study. Although the duration might be
inconsistent and influenced by the attitude of both patients
and doctors, duration of diabetes does reflect the residual
b-cell mass in T2DM patients. This study and others also
support the thesis that duration of diabetes is probably
more important than type of surgery to predict a successful
result of surgical treatment of diabetes.25e27 Therefore,
duration of diabetes may not only be a criterion for patient
selection but also for choice of different surgical
procedure.
Type of surgery was another independent predictor by
multivariate analysis in the present study. Gastric bypass
has been proven to have a better weight reduction and
higher diabetes remission rate compared with purely
restrictive procedures. Although less effective in diabetes
remission than gastric bypass surgery, restrictive type
surgery is 10 times safer than a complex gastric bypass
procedure,8 and avoids the long-term sequelae of micro-
nutrient deficiency following duodenum exclusion,28,29 and
should still be considered as the first choice in gastroin-
testinal metabolic surgery.30 For restrictive type surgery,
Dixon et al have reported a T2DM remission rate of 73% for
gastric banding, which is much higher than the 45% in the
present study.12 However, in the study of Dixon et al, only
newly diagnosed patients with duration of T2DM < 2 years
were recruited. In this study, the remission rate of
restrictive type surgery for those with duration of T2DM < 2
years was 100%. For other restrictive type surgery, Vidal
et al also have reported a 100% T2DM remission rate in
patients with morbid obesity receiving sleeve gastrec-
tomy.31 In the study of Vidal et al, the patients were all
morbidly obese with a mean BMI of up to 51.9 kg/m2 but no
duration of T2DM was available. However, another recent
study also has reported that remission of T2DM after sleeve
gastrectomy dropped to 13% in those with duration of T2DM
> 5 years, which is similar to the present study.27 For
gastric bypass, a recent study has demonstrated a decrease
in diabetes remission in patients with duration of T2DM >
10 years.32 Taken together, for choice of surgical proce-
dures, gastric banding may be considered for diabetes
treatment in patients with duration of T2DM < 2 years. The
recommended selection criteria for sleeve gastrectomy
may be patients with duration of T2DM < 5 years. Sleeve
gastrectomy has a better effect on weight loss than gastric
banding; probably because of changes in ghrelin.33 Gastric
bypass surgery is recommended for the rest of T2DM
patients but they should have C-peptide > 1 ng/mL with
central obesity.34 Further studies are required before
conclusions are drawn about other surgical procedures.16
Figure 1 Relative importance of preoperative predictor variables for diabetes remission (significant factor was defined by those
with percent contribution > 10). AlbZ albumin; ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; BMZ body
mass index; CHOZ total cholesterol; DBPZ diastolic blood pressure; HbZ hemoglobin; HDL-CZ high-density lipoprotein
cholesterol; HOMA-IRZ homeostasis model assessmenteinsulin resistance; hsCRPZ high-sensitivity C-reactive protein;
MSZmetabolic syndrome; OPZmethods of surgery; SBPZ systolic blood pressure; TGZ triglyceride.
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surgery is intriguing. Both restrictive and bypass surgery
had been reported to be effective for remission of associ-
ated T2DM in patients with morbid obesity. In our previous
study, both types of surgery were effective in reducing of IR
but the mechanism was related to a caloric effect in the
early phase and related to weight loss in the late phase.35 In
a meta-analysis, remission of T2DM after bariatric surgery
was dose-dependent for weight loss rather than procedure-
dependent.8 For a long-term effect on remission of T2DM,
sustained weight reduction plays a key role. However,
recent studies have suggested the superior effect of gastric
bypass over restricted procedures owing to a direct effect
of bypass of the hormonally active foregut.36 Rubino and
Marescaus have supported the theory in an animal
model.37,38 Other studies also have demonstrated an
increase in the hindgut hormones, such as GLP-1 and PYY
after gastric bypass.39,40 In the present study, the bypass
group did have a higher T2DM remission rate compared to
the restrictive group. Although the remission of T2DM
seems to correlate with weight reduction in different
groups, the bypass group had a superior advantage in T2DM
remission, other than via weight loss.
Age was also a significant predictor by ANN analysis in
the present study. Old age reflected a deteriorating
pancreatic preserve and diminished B-cell reserve, which
might be evaluated by C-peptide level. C-peptide isTable 5 T2DM remission rate according to disease duration.
Duration (yr) < 2 2e
All patients 98.5% (57/59) 39
Bypass group 98.1% (51/53) 55
Restrictive group 100.0% (6/6) 25
T2DMZ type 2 diabetes mellitus.
*p< 0.05.a connecting peptide to insulin and a valuable test in the
classification of diabetes. Type 1 DM has low C-peptide
levels, whereas in T2DM, C-peptide levels are above normal
due to a compensatory increase in insulin production.
However, in late stage T2DM, as b-cells are progressively
destroyed, C-peptide level may become low.41,42 There-
fore, C-peptide levels in T2DM patients may reflect their
pancreas preserve and predict the success of surgical
treatment of T2DM. Preoperative C-peptide was found to
be an important predictor of diabetes remission after
sleeve gastrectomy in a recent study.42 In our study, the
preoperative C-peptide level could also be used as
a predictor of successful treatment, especially in restric-
tive type surgery. Although not an independent predictor,
C-peptide levels in T2DM patients may reflect their
pancreatic preserve and should be included in evaluating
surgical treatment for T2DM.33 Other potential predictors
for diabetes remission after surgical treatment, such as
stimulated C-peptide level and incretin effect of the
patients, require further exploration.
There were several limitations to this study. First, the
case number was small. Although sleeve gastrectomy and
gastric banding seem to result in different weight loss and
gut hormone modulation,32 we did not have enough
patients to analyze this point. Second, the 1-year follow-up
period was short. The maximal weight reduction effect of
restrictive surgery was > 1 year, although maximal weight5 > 5 p
.3% (7/17) 33.3% (4/12) 0.000*
.6% (5/9) 50.0% (3/6) 0.005*
.0% (2/8) 16.7% (1/6) 0.000*
Table 6 T2DM remission rate according to preoperative C-peptide levels.
C-peptide (ng/mL) <3 3e6 >6 p
All patients 60% (9/18) 75.7% (25/33) 90.1% (19/21) 0.001*
Bypass group 71.4% (7/12) 92.3% (24/26) 93.3% (14/15) 0.014*
Restrictive group 33.3% (2/6) 14.3% (1/7) 83.3% (5/6) 0.037*
*p< 0.05.
72 W.-J. Lee et al.loss usually happens within 1 year. The best diabetes
remission effect of restrictive surgery might also be at > 1
year. Further study with longer follow-up is required to
confirm this finding, as well as the durability of T2DM
remission after bariatric surgery. Finally, this study was
retrospective and procedure choice by the patient may
have been biased and affected the conclusions.
A randomized clinical trial is indicated before any firm
conclusions can be made.
In conclusion, bariatric or gastrointestinal metabolic
surgery is a promising treatment for inadequately
controlled obesity-related T2DM patients with a 77.2%
remission rate for associated diabetes. Although gastric
bypass surgery is more effective for diabetes remission than
restrictive type surgery, duration of diabetes is the most
important predictor of diabetes remission after surgery.
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